Kenya is discussing measures to combat the growth of drug-resistant illnesses while providing patients with additional life-saving medications with a private company.
Dr. Ouma Oluga, the principal secretary for medical services, met Dr. Angus L. C. O’Shea, the chief executive of Aranda, at his office. The two parties talked about how to reinforce controls against antimicrobial resistance, or AMR and increase access to necessary antibiotics. AMR occurs when germs become resistant to medications intended to eradicate them. It makes treating common infections more difficult and often impossible.
The two presidents are still in negotiations that started in September on the fringes of the UN General Assembly in New York. Kenya’s health system is already being examined by Aranda. The Social Health Authority, KEMSA and the county governments of Nairobi, Kiambu and Murang’a have all held discussions with the corporation.
Dr. Oluga clarified the Ministry’s stance. Improved testing, cautious prescribing and strict monitoring must go side in hand with increasing access to antibiotics. Any collaboration, he stressed, must function within the current national and local frameworks. Neither KEMSA nor the Social Health Authority should be circumvented by the creation of new parallel institutions. Additionally, he emphasized the need of long-term outcomes and good value for money in order to help Kenya’s efforts to achieve universal health care.
The issue is already familiar to many Kenyan families. A youngster may require a particular antibiotic for a chest infection, yet public facilities can lack the appropriate medication. However, several of those medications are now less effective due to past abuse of antibiotics. The true problem behind these discussions is figuring out how to provide patients with the appropriate medications without exacerbating resistance.
The talks are still in their early stages. There has been no announcement of a schedule, pricing structure or specific agreement. The Ministry has requested that Aranda submit concise, Kenya-specific proposals outlining how any collaboration would operate in reality, how it would be funded and what public health outcomes it would produce.
Aranda has to take the next step. The business has been asked to provide recommendations that are supported by evidence. According to the Ministry, any future collaboration will be evaluated based on how it affects regular patients, how much it costs, how sustainable it is and how well it integrates into Kenya’s current healthcare system. For the time the discussions indicate that the battle against resistance and the availability of antibiotics are viewed as two aspects of the same issue.
